We are a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases. Finding the right starting points to target diseases at their source.
Using a combination of a systematic assessment of the genetic disease landscape and informed diligence on the latest research, we find indications with clear mechanisms of pathogenesis that are ripe for translation into disease-modifying drugs.
Crinetics Pharmaceuticals explores the inner life of GPCRs to discover and develop novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers. A team of scientists with a proven track record of endocrine drug discovery and development founded the company to create important new therapeutic options for endocrinologists and their patients.
Eidos Therapeutics is a clinical biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. Eidos seeks to treat this well-defined family of diseases at their collective source by stabilizing TTR.
IDEAYA is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, the Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by three Members of the National Academy of Sciences.
Kodiak is a high-science retinal medicines development company. We are aspiring to build a dominant global retina franchise. We are developing a top pipeline of proprietary best-in-class medicines for the treatment of patients with age-related macular degeneration and diabetic eye disease, two leading causes of blindness. Our science begins with an antibody biopolymer product platform merging the fields of biologics and chemistry based therapies. In our medicines we aim to restore vision, to stop progression of underlying disease, and to require fewer treatments.
Landos’ unique core platform technology enables accelerated development of safer, more effective oral, first-in-class therapeutics for autoimmune diseases. Landos has identified Lanthionine Synthetase C-Like 2 (LANCL2) as a novel therapeutic target for autoimmune diseases, including inflammatory bowel disease (IBD); Crohn’s disease (CD) and ulcerative colitis (UC). Based on extensive preclinical studies, Landos has validated a unique mechanism of action involving LANCL2 that exerts potent anti-inflammatory effects with an outstanding safety profile.
MeiraGTx develops innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (AMD). MeiraGTx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. We are pioneering the use of gene therapy to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). MeiraGTx is developing novel gene regulation platforms that promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
Outset Medical is focused on reimagining the experience of dialysis care for patients with kidney disease by providing them greater flexibility, independence, and control with the potential to dramatically lower cost for providers and the healthcare system.
PTx has acquired the global rights to develop, manufacture, and commercialize Leukine from Sanofi. Leukine is a multi-lineage immune-stimulant that has been demonstrated to promote growth and activation of monocytes, macrophages, neutrophils and dendritic cells. It is the only FDA-approved recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF). Leukine is currently being tested in over 100 clinical studies to assess its ability to increase the efficacy of immuno-oncology therapies, improve the treatment of pulmonary and neurological disorders, and improve the treatment of infections. PTx is an integrated commercial stage biotech company focused on the development and commercialization of therapeutics that improve health and economic outcomes in the treatment of cancer.
PROCEPT BioRobotics is a privately held surgical robotics company enabling better patient care by developing transformative solutions in urology. With an initial focus on benign prostatic hyperplasia (BPH), PROCEPT has developed Aquablation® therapy, a novel and disruptive treatment for enlarged prostate. The company’s first product, the AquaBeam® System, is the world’s first surgical robot providing autonomous tissue removal for the safe and effective treatment of BPH, independent of prostate anatomy or surgeon experience.
QSpex is transforming the vision industry by combining best-in-class lens technology with an unprecedented level of service. Transforming the optical industry by offering premium prescription eyewear, fulfilled SAME-DAY, through a personalized delivery and dispensing process. Our high-speed, proprietary Rapid Lens Technology™ eliminates the pitfalls of traditional lens manufacturing. Using QSpex’s groundbreaking Touchless Transfer™ lens system, Rapid Lens Technology™ provides premium prescription eyewear through unique, covalently bonded treatments.
Renovia was formed to better diagnose, treat, and potentially improve the lives of millions of women through a platform of innovative sensor technologies combined with a digital health platform. This allows precise, cost-effective visualization and treatment of weakened pelvic floor muscles in real time, while collecting actionable compliance and progress data on women’s pelvic health. Restoring pelvic health by strengthening pelvic floor muscles through clinically benefiting solutions is paramount to treating the underlying causes of Pelvic Floor Disorders.
A private company focused on acquiring and developing disease modifying therapies for Duchenne Muscular Dystrophy through rigorous scientific analysis, efficient capital management and global collaborations.
Tivorsan Pharmaceuticals is a protein therapeutics company pioneering a unique approach to treat serious neuromuscular disorders, including Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD).
Vapotherm is dedicated to the development, manufacture and marketing of respiratory devices that improve clinical outcomes, reduce overall delivery cost and improve quality of life for patients. Vapotherm High Flow Therapy provides support for patients in respiratory distress and has been used in over half a million patients.
Vensun Pharmaceuticals is an emerging generic pharmaceutical company developing a portfolio of difficult to access or hard to formulate generic prescription products.
Verrica Pharmaceuticals is a clinical-stage pharmaceutical company developing proprietary topical therapies for the treatment of skin diseases such as Verruca vulgaris (common warts and plantar warts) and Molluscum contagiosum. Current treatments for these and similar conditions have only limited efficacy, are painful or require daily compliance for an extended treatment period to see results.
Vitruvias is a specialty generic pharmaceutical business focused on the development and marketing of generic products with either (i) complex APIs that are difficult to source, or (ii) finished dosage forms that are inherently difficult to manufacture. The highly skilled team at Vitruvias has expertise in all aspects of the pharmaceutical industry, including product development, licensing, regulatory affairs, marketing, financial analysis, distribution, managed care, trade relations and sales.
Vyome Biosciences is an innovation driven company, with a vision to develop novel drugs for antibiotics-resistant acne and other opportunist pathogens through a unique pipeline of antibiotics that retard resistance development.
Xontogeny (zon-TOJ-uh-nee) is a biotech aggregator with a differentiated business model to support the accelerated development of life science technologies in the pursuit of helping patients with serious diseases. Speciﬁcally, we partner with entrepreneurs, providing the leadership and operating experience needed to increase the probability of success with early drug and technology development.